ScripLeading South Korean antibody-drug conjugate (ADC) specialist LigaChem Biosciences has made a $25m investment for an initial 26.6% equity stake in existing partner IKSUDA Therapeutics, and secured the
ScripIonis licensed global rights to Phase II polycythemia vera (PV) candidate sapablursen to Ono Pharmaceutical on 11 March. The deal provides near-term and longer-term revenue for a drug candidate the an
ScripMerck KGaA only has two-late stage candidates in its pipeline but CEO Belén Garijo has told Scrip that the German company is laser-focused on adding more assets. Speaking at Merck’s annual press con
Scrip2024 was an eventful year for the South Korean biopharma industry with the emergence of several key themes that look set to carry over into the new year. The sector is facing a new growth chapter fuel